ストックスクリーナーアプリを入手
3.44
6.52%
-0.24
前日終値:
$3.68
開ける：
$3.68
24時間の取引高:
715.86K
Relative Volume:
1.20
時価総額：
$207.85M
収益：
$40.37M
当期純損益:
$-119.72M
株価収益率:
-1.6861
EPS:
-2.0402
ネットキャッシュフロー:
$-135.06M
1週間 パフォーマンス:
-8.99%
1か月 パフォーマンス:
+3.61%
6か月 パフォーマンス:
-14.43%
1年 パフォーマンス:
-3.10%
1日の値動き範囲:
$3.415
$3.68
1週間の範囲:
$3.415
$3.83
52週間の値動き範囲:
$2.8838
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
名前
Voyager Therapeutics Inc
セクター
電話
857-259-5340
住所
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.44 | 207.85M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 開始されました | Citigroup | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-10-16 | 開始されました | Leerink Partners | Outperform |
| 2024-03-26 | 開始されました | Guggenheim | Buy |
| 2024-03-19 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-07 | 開始されました | Citigroup | Buy |
| 2024-01-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 開始されました | Truist | Buy |
| 2023-03-10 | 開始されました | Oppenheimer | Outperform |
| 2021-10-07 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | ダウングレード | BTIG Research | Buy → Neutral |
| 2021-02-03 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-24 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-11-10 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 開始されました | The Benchmark Company | Buy |
| 2020-02-06 | 開始されました | Oppenheimer | Outperform |
| 2018-11-15 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-09-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-02-02 | 開始されました | Morgan Stanley | Overweight |
| 2017-11-28 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2017-10-27 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-23 | 繰り返されました | Stifel | Buy |
| 2017-10-12 | 開始されました | Raymond James | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-28 | 再開されました | Stifel | Buy |
すべてを表示
Voyager Therapeutics Inc (VYGR) 最新ニュース
Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase - ad-hoc-news.de
Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets - ad-hoc-news.de
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
VYGRVoyager Therapeutics Inc Latest SEC Filings - Finviz
Voyager Therapeutics : VYGR - 24/7 Wall St.
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Insider Monkey
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Price to earnings forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Enterprise value to EBITDA forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Voyager to present Alzheimer’s gene therapy data at AAIC - Investing.com UK
Voyager to present Alzheimer’s gene therapy data at AAIC By Investing.com - Investing.com Australia
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s - GlobeNewswire
VYGR Forecast — Price Target — Prediction for 2027 - TradingView
Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR) - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6) - TradingView
VT6 Forecast — Price Target — Prediction for 2027 - TradingView
Voyager Therapeutics Inc (VYGR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Voyager Therapeutics Inc (VYGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TD Cowen Maintains Voyager Therapeutics(VYGR.US) With Buy Rating - Moomoo
Voyager Therapeutics, Inc. Stock 12‑Month Price Target Raised to $15.38, Implies 325% Upside - TradingView
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Institutional Confidence - TradingKey
Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc (VYGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Onyia Jude - Moomoo
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics Inc (VYGR) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):